ClinicalTrials.gg
CompletedNCT06526884NDCUpdated May 18, 2026

Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC)

An interventional study of Next Day Clinic in Pneumonia, Syncope and Congestive Heart Failure, sponsored by University of California, Los Angeles. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
570
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. The way it does this is by identifying patients in the ED who would normally be admitted for low-acuity conditions, and diverting them to a high-acuity clinic the following day called the NDC. This will help decompress the ED and the hospital, and allow for overall higher quality care. The Health System has partnered with UCLA's Healthcare Value Analytics and Solutions [UVAS] group which specializes in these types of program evaluations. The analysis conducted by the study team will be used to directly inform NDC operations, scaling, and future plans.

Read the detailed description

NDC is a hospital avoidance model with the potential to simultaneously improve the quality and safety of acute care, reduce costs, and address hospital/ED overcrowding. This novel hospital avoidance program will divert patients from the ED who have been diagnosed with the following conditions and meet certain clinical criteria:

  • Diabetic Foot Infection/Osteomyelitis
  • Cellulitis
  • Congestive Heart Failure
  • Syncope
  • Pyelonephritis/Urinary Tract Infection
  • Pneumonia
  • Acute Kidney Infection
02

Conditions studied

  • Pneumonia
  • Syncope
  • Congestive Heart Failure
  • Cellulitis
  • Pyelonephritis
  • AKI - Acute Kidney Injury
  • Diabetic Foot Infection
  • Osteomyelitis

Keywords

  • Patient safety
  • Cost effectiveness
  • Avoidable hospitalizations
03

In context

Pneumonia

1,564 studies on the registry are indexed under Pneumonia; 265 are open to participants now.

This study's enrollment of 570 is above the median of 129 across 975 interventional studies indexed under Pneumonia.

Browse Pneumonia studies →

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,170 studies on the registry; 195 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • About to be admitted through the ED for one of the NDC diagnoses or a synonym (per Study Protocol document), defined by the presence of a Plan to Admit order or Bed Request order, OR recently admitted under observation or inpatient status for one of the NDC diagnoses.
  • Identified as at-risk for an avoidable hospitalization in the ED based on a pre-determined set of lab and vital parameters.
  • Insurance that authorizes the patient to follow-up at UCLA Health, or self-pay
  • Admitted or being admitted to an internal medicine service

Exclusion criteria

Exclusion Criteria:

  • Heart or lung transplant recipient with concern for graft dysfunction
  • Pregnant
  • Enrolled in hospice
  • Admitted to a critical care service
  • ED deems discharge unsafe due to complex social or medical factors
  • Active malignant cancer (per Council of State and Territorial Epidemiologists value set)
  • Pulmonary arterial hypertension (per Joint Commission value set)
  • Undergoing workup for solid organ transplant
  • Interstitial lung disease (including pulmonary fibrosis) (per Higher Level 7 value set)
  • Requiring inpatient procedure or surgery defined by the presence of an anesthesia event or operating room encounter.
  • The ED deems discharge unsafe due to complex social or medical factors.
  • Transferred to an ineligible hospital

Note:

The Health System plans to limit the volume of referrals to the NDC by only referring patients who have an even birth date (this is more equitable than first-come-first-serve, because wage workers are more likely to come to the ED later in the day; even/odd birth date theoretically keeps more spots open for patients presenting to the ED later).

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
570 participants (actual)

Study arms

  • No intervention
    ED-initiated hospitalization

    Patients with odd birthdays will be routed to standard-of-care ED-initiated hospitalization pathways.

  • Experimental
    Next Day Clinic

    Patients with even birthdays who meet inclusion criteria will be given the option to receive care in the Next Day Clinic to avoid hospitalization.

    Other: Next Day Clinic

Interventions

  • OtherNext Day Clinic

    A dedicated Next Day Clinic team consisting of a clinician and nurse case manager will provide care and specialist referrals to patients within 24 hours of an ED visit that would have resulted in hospitalization without this novel hospital avoidance initiative.

06

What researchers measure

Primary outcomes

  1. Days alive and out of hospital (DAOH)

    Cumulative number of days alive and not admitted or boarding in a hospital or emergency department

    Time frame: 30 days from index ED visit

Secondary outcomes

  1. Global health-related quality of life

    Composite PROMIS-29+2 score (patient reported outcome measurement information system). PROMIS stands for Patient-Reported Outcomes Measurement Information System. High scores mean more of the concept being measured.

    Time frame: 30 days from index ED visit

  2. Patient experience

    Measured by PSQ-18 (patient satisfaction questionnaire). PSQ stands for Patient Satisfaction Questionnaire. High scores indicate higher levels of satisfaction.

    Time frame: 30 days from index ED visit

  3. Financial analysis

    Total cost per day of treatment

    Time frame: Through study completion, an average of 12 months

  4. Cost effectiveness analysis

    Total cost per day alive and out of hospital

    Time frame: Through study completion, an average of 12 months

  5. Hospitalizations avoided

    Each NDC referral with a preceding Plan to Admit order or Bed Request order (regardless of treatment arm) will be considered an avoided hospitalization, given that the presence of one of these orders establishes that the counterfactual for NDC treatment in hospitalization.

    Time frame: Through study completion, an average of 12 months

  6. Hospital bed-days saved

    For each referral to the NDC, the number of hospital bed-days saved will be established by using the mean length of stay for patients treated per-protocol in the control condition matched for the same presenting illness.

    Time frame: Through study completion, an average of 12 months

07

Study locations

1 site
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90024, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified data may be uploaded to a data repository system such as Vivli.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06526884
Responsible party
Richard K. Leuchter, MD (Assistant Professor, University of California, Los Angeles) — Principal investigator
First posted
Jul 30, 2024
Start date
Jul 22, 2024
Primary completion
Jan 20, 2026
Completion
Mar 31, 2026
Last update
May 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion